Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
B cell malignancies
CAR‐T cell therapy
Phase I trial
first‐generation
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
18
04
2023
revised:
25
05
2023
accepted:
29
05
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.
Identifiants
pubmed: 37601889
doi: 10.1002/jha2.731
pii: JHA2731
pmc: PMC10435680
doi:
Types de publication
Journal Article
Langues
eng
Pagination
882-885Informations de copyright
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
FT: Scientific Advisory Board member (T‐Knife), Advisory Board Honoraria (GSK, Ixaka, Janssen, Lucid Bio, Pfizer, Scenic Biotech). RH: Founder and Head of R&D (Instil Bio). DG: stock options (Celyad Oncology) and share holder (Instil Bio). The other authors have no competing interests.
Références
J Exp Med. 1995 May 1;181(5):1653-9
pubmed: 7722445
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Br J Haematol. 2005 May;129(3):322-32
pubmed: 15842655
BMC Cancer. 2022 Jan 24;22(1):98
pubmed: 35073859
J Adv Pract Oncol. 2019 May-Jun;10(Suppl 3):21-28
pubmed: 33520343
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147